India Globalization Capital Inc. (NYSE American: IGC) Is 'One To Watch'
Date
12/20/2024 4:07:06 AM
(MENAFN- Investor Brand Network)
- IGC's leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer's dementia
- As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC based formulation on Alzheimer's patients
- The company's other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer's cell lines
- Alzheimer's disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S.
India Globalization Capital (NYSE American: IGC) , through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer's disease, Tourette syndrome, chronic pain, and pet seizures.
IGC's leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer's dementia, the first study in humans of a natural tetrahydrocannabinol (“THC”) compound plus another molecule...
Read More>>
NOTE TO INVESTORS:
The latest news and updates relating to IGC are available in the company's newsroom at
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing
CBDNewsBreaks
crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published:
Do you have questions or are you interested in working with CNW?
Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
303.498.7722 Office
[email protected]
CBDWire is part of the
InvestorBrandNetwork .
MENAFN20122024000224011066ID1109015615
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.